Indoco Remedies Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Sundeep Bambolkar

Chief executive officer

₹65.5m

Total compensation

CEO salary percentage	60.6%
CEO tenure	12.2yrs
CEO ownership	n/a
Management average tenure	7.3yrs
Board average tenure	13.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sundeep Bambolkar's remuneration changed compared to Indoco Remedies's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	₹1b
Sep 30 2023	n/a	n/a	₹1b
Jun 30 2023	n/a	n/a	₹1b
Mar 31 2023	₹65m	₹40m	₹1b
Dec 31 2022	n/a	n/a	₹2b
Sep 30 2022	n/a	n/a	₹2b
Jun 30 2022	n/a	n/a	₹2b
Mar 31 2022	₹46m	₹30m	₹2b
Dec 31 2021	n/a	n/a	₹1b
Sep 30 2021	n/a	n/a	₹1b
Jun 30 2021	n/a	n/a	₹1b
Mar 31 2021	₹28m	₹20m	₹930m
Dec 31 2020	n/a	n/a	₹734m
Sep 30 2020	n/a	n/a	₹571m
Jun 30 2020	n/a	n/a	₹393m
Mar 31 2020	₹18m	₹15m	₹241m
Dec 31 2019	n/a	n/a	₹302m
Sep 30 2019	n/a	n/a	₹264m
Jun 30 2019	n/a	n/a	₹111m
Mar 31 2019	₹15m	₹12m	-₹29m
Mar 31 2018	₹16m	₹12m	₹412m

Compensation vs Market: Sundeep's total compensation ($USD785.18K) is above average for companies of similar size in the Indian market ($USD271.17K).

Compensation vs Earnings: Sundeep's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Sundeep Bambolkar (63 yo)

12.2yrs

Tenure

₹65,497,000

Compensation

Mr. Sundeep Vasant Bambolkar has been a Joint Managing Director at Indoco Remedies Limited since February 15, 2012. Mr. Bambolkar served as Chief Financial Officer at Indoco Remedies Limited from March 23,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Suresh Kare	Non-Executive Chairman & Whole time Director	60.8yrs	₹53.92m	4.7% ₹ 1.4b
Sundeep Bambolkar	Joint MD & Executive Director	12.2yrs	₹65.50m	no data
Aditi Panandikar	MD & Executive Director	12.2yrs	₹73.93m	6.09% ₹ 1.8b
Pramod Ghorpade	Chief Financial Officer	2.4yrs	₹14.91m	no data
Ramanathan Hariharan	GM of Legal	1.3yrs	₹3.83m	no data
A. Rege	President of Operations	no data	no data	no data
Kavita Inamdar	Chief Technical Officer	no data	₹7.57m	no data
Bandari Kumar	Senior Vice President of Marketing	no data	no data	no data
Vilas Nagare	President of Corporate Affairs and M&A	no data	no data	no data

7.3yrs

Average Tenure

59.5yo

Average Age

Experienced Management: 532612's management team is seasoned and experienced (7.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Suresh Kare	Non-Executive Chairman & Whole time Director	60.8yrs	₹53.92m	4.7% ₹ 1.4b
Sundeep Bambolkar	Joint MD & Executive Director	20.1yrs	₹65.50m	no data
Aditi Panandikar	MD & Executive Director	20.1yrs	₹73.93m	6.09% ₹ 1.8b
Divakar Gavaskar	Independent Non-Executive Director	19yrs	₹640.00k	no data
Rajiv Kakodkar	Independent Non-Executive Director	17yrs	₹720.00k	0.013% ₹ 3.9m
Anand Nadkarni	Non-Executive Director	9.9yrs	₹360.00k	no data
Vasudha Kamat	Non-Executive & Independent Director	4.1yrs	₹560.00k	no data
Abhijit Gore	Independent Non-Executive Director	3.5yrs	₹520.00k	0.0054% ₹ 1.6m
Satish Shenoy	Independent Director	less than a year	no data	no data
Ajay Mulgaokar	Independent Director	less than a year	no data	no data

13.5yrs

Average Tenure

66yo

Average Age

Experienced Board: 532612's board of directors are seasoned and experienced ( 13.5 years average tenure).

Indoco Remedies Management

Management criteria checks 2/4

Key information

Recent management updates

Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024

Insufficient new directors

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2023

MD & Executive Director recently bought ₹6.4m worth of stock

MD & Executive Director recently bought ₹1.6m worth of stock

MD & Executive Director recently bought ₹669k worth of stock

Recent updates

Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2024 Results on Jan 23, 2024

Insufficient new directors

Indoco Remedies Limited to Report Q2, 2024 Results on Oct 19, 2023

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2023

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q1, 2024 Results on Jul 25, 2023

MD & Executive Director recently bought ₹6.4m worth of stock

MD & Executive Director recently bought ₹1.6m worth of stock

Indoco Remedies Limited (NSEI:INDOCO) agreed to acquire a 85% stake in Florida Pharmaceutical Products, Inc. from Contract Pharmacal Corp. for $4 million.

Indoco Remedies Limited Recommends Dividend for the Financial Year 2022-2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q4, 2023 Results on May 23, 2023

MD & Executive Director recently bought ₹669k worth of stock

Insufficient new directors

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2023 Results on Jan 24, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited Announces Executive Changes

Indoco Remedies Limited to Report Q2, 2023 Results on Nov 10, 2022

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Indoco Remedies Limited Announces Anacipher CRO Clears USFDA Inspection with Zero 483S

Upcoming dividend of ₹2.25 per share

Indoco Remedies Limited, Annual General Meeting, Sep 22, 2022

Indoco Remedies Limited (BSE:532612) agreed to acquire 26% stake in Kanakal Wind Energy Private Limited for INR 8.64 million.

First quarter 2023 earnings released: EPS: ₹4.19 (vs ₹4.30 in 1Q 2022)

Indoco Remedies Limited to Report Q1, 2023 Results on Aug 09, 2022

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Indoco Remedies Limited to Report Q4, 2022 Results on May 17, 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Second quarter 2022 earnings released: EPS ₹4.52 (vs ₹2.78 in 2Q 2021)

Upcoming dividend of ₹1.50 per share

First quarter 2022 earnings released: EPS ₹4.30 (vs ₹1.85 in 1Q 2021)

Consensus EPS estimates increase to ₹17.85

Investor sentiment improved over the past week

Chief Financial Officer Mandar Borkar has left the company

Full year 2021 earnings released: EPS ₹10.10 (vs ₹2.62 in FY 2020)

Indoco Remedies Limited Recommends Dividend for the Financial Year 2020-2021

Price target increased to ₹361

Indoco Announces the Launch of Brinzolamide Ophthalmic Suspension 1% in the US Market by Teva Pharmaceuticals

Third quarter 2021 earnings released: EPS ₹2.75 (vs ₹0.99 in 3Q 2020)

New 90-day high: ₹326

Indoco Remedies Limited to Report Q3, 2021 Results on Feb 09, 2021

New 90-day high: ₹313

Market bids up stock over the past week

New 90-day high: ₹290

Price target raised to ₹275

Second quarter 2021 earnings released: EPS ₹2.78

Indoco Remedies Limited Appoints Abhijit Yashwant Gore as an Additional Director

Indoco Remedies Limited Announces Retirement of Sharad P Upasani as Non- Executive Independent Director

Indoco Remedies Limited Launches FEVINDO 400 (Favipiravir 400mg Tablets)

New 90-day high - ₹268

Upcoming Dividend of ₹0.30 Per Share

New 90-day high - ₹241

Indoco Remedies Limited to Report Q1, 2021 Results on Aug 11, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure